Yesterday | Drug Store News
Addex finds GERD drug effective in clinical trial
GENEVA An investigational drug in mid-stage clinical trials that is the first of its class effectively treats symptoms of gastroesophageal reflux disease, according to study results recently released by the manufacturer.
'Heartburn' Damage Or GERD Not Acid Burn
Reflux damage to the esophagus may be an immune response, not acid burn, U.S. researchers say.
My GERD Diet has evolved through a simple process of elimination. Doctors told me when I was first diagnosed with GERD that I should go on a strict GERD diet.
Conservative vs surgical treatment for obesity with GERD
December's issue of the Alimentary Pharmacology & Therapeutics reviews the effects of conservative and surgical treatment for obesity on gastro-esophageal reflux disease.
PRINCETON,A N.J The generics arm of Swiss pharmaceutical company Novartis has launched an authorized generic version of a gastroesophageal reflux disease drug.
Addex ADX10059 Monotherapy is Effective on GERD Symptoms in Phase IIb Clinical Trial
Webcast Today at 4pm CET Highlighted Links Homepage GENEVA, SWITZERLAND-- - Addex Pharmaceuticals , the allosteric modulation company, announced that it achieved statistically significant efficacy on the primary endpoint, increasing the number of symptom free days in the Phase IIb trial of ADX10059 as a monotherapy in patients with gastroesophageal ...
7 Simple Changes That Help Ease Heartburn
Meals are often a trigger for GERD symptoms. In fact, all-you-can-eat buffets are almost always a recipe for heartburn.
Open Wide: Incisionless Surgery to Treat GERD
Every day, more than 20 percent of the U.S. population experiences the painful burning symptoms of gastroesophageal reflux disease .
New surgery brings relief from GERD
Connie Braswell anticipates doing something this Thanksgiving she hasn't enjoyed in five years - eating.
Surgery Without an Incision? Now That's a Medical Advance
It's being called the next step in the evolution of surgery. Surgery without an incision doesn't even sound like surgery, but for the 60 million people in the United States who suffer from Gastroesophageal Reflux Disease or chronic acid reflux, it's a new treatment option they can get excited about.
Today's expert is Dr. Nikhilesh Sekhar, Surgical Associates of Neenah, Theda Clark Medical Center.
Long-term outcome of laparoscopic and conventional nissen fundoplication
The most recent issue of Annals of Surgery investigated the 10-year outcome of laparoscopic and conventional nissen fundoplication.
Heartburn Linked to Stress in 9/11 Workers
World Trade Center workers who were at Ground Zero for months after September 11, 2001, continue to have higher-than-normal rates of heartburn and acid reflux even years later.
GERD Drugs May Cause Unexpected Side Effects
People who are taking drugs called proton pump inhibitors to treat GERD and laryngopharyngeal reflux should be aware of possible unexpected side effects and complications, according to a new report published in Otolaryngologya 'Head and Neck Surgery .
Could surgery help your reflux?
Losing weight, raising the head of the bed, not eating late at night: All of these can help alleviate the symptoms of gastroesophageal reflux disease, or GERD.
Heartburn: Are you spending too much on treatment?
How much money do you really need to spend to treat frequent heartburn or even acid reflux? $250 a month? $120 a month? Try as little as $24. Last year U.S. consumers and their insurance companies spent an astonishing $4.8 billion on Nexium, one of several prescription proton-pump inhibitors to treat heartburn and acid reflux.
Halloween is tricky for anyone watching her waistline, but for chronic heartburn sufferers, all those goodies can make for a miserable night.
Positive Data from Two Investigator-Initiated Studies with Santarusa ZEGERID to Be Presented At ACG
Santarus, Inc. , a specialty biopharmaceutical company, today announced that positive data from two investigator-initiated studies with ZEGERID will be presented in poster sessions at the American College of Gastroenterology 2009 Annual Scientific Meeting taking place in San Diego.
XenoPort Announces Initiation of a Phase 2b Clinical Trial of...
XenoPort, Inc. announced today that it has initiated a Phase 2b clinical trial of arbaclofen placarbil , also known as XP19986, in patients with gastroesophageal reflux disease who remain symptomatic despite treatment with a proton pump inhibitor .
Put an end to the misery. Sarah Baldauf and January W. Payne Premium Health News Service October 14, 2009 Sign Up Today for HK Newsletters & Alerts There's something about digestive difficulties that makes them hard to discuss in polite company--which leaves many of us suffering one problem or another in silence.
Also on Topix